- In March 2025, A comprehensive analysis of the CIDP pipeline highlights a promising future with emerging therapies. Notable developments include Sanofi's Riliprubart, an IgG4 humanized monoclonal antibody in Phase III clinical trials, and Immunovant Sciences GmbH's Batoclimab, an FcRn antagonist in a Phase II study. These indicate a shift towards novel treatment modalities and a strong industry commitment to addressing unmet needs in the CIDP community
- In May 2025, Nuvig Therapeutics announced that the first patient has been dosed in its Phase 2 clinical trial evaluating NVG-2089 for CIDP. NVG-2089 is a recombinant human IgG1-Fc fusion protein designed to mimic the immunomodulatory mechanisms of intravenous immunoglobulin (IVIg), aiming to provide a more consistent, scalable, and convenient alternative to the current standard of care
- In March 2025, Muscular Dystrophy Association Clinical & Scientific Conference underscored the substantial clinical and economic burden of CIDP on healthcare systems, caregivers, and patients. This highlights the ongoing need for improved management strategies and support networks, driving further research and development in the field
- In January 2024, Takeda Pharmaceutical Company Limited received FDA approval for its GAMMAGARD LIQUID as an IVIG therapy for adults diagnosed with CIDP. This approval supports long-term disease management and aims to improve neuromuscular function, reinforcing IVIG as a cornerstone of CIDP treatment
- In June 2024, The U.S. Food and Drug Administration approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of CIDP in adults. This subcutaneous injection offers a new therapeutic option for patients, demonstrated to significantly extend the time to clinical deterioration compared to placebo
